(Q36811133)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

0 references

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Yang ZR

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Wang HF

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Zhao J

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Peng YY

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Wang J

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Huang LQ

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

1 reference

20 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

599-615

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17479105%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701054

30 December 2019

exact match

0 references

cites work

Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

Transductional targeting of adenoviral cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

Radiation Therapy—Activation of Gene Transcription and the Development of Genetic Radiotherapy: Therapeutic Strategies in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

Gene therapy clinical trials worldwide 1989-2004-an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Recovery of new agent from patients with acute respiratory illness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Large, persistent epidemic of adenovirus type 4-associated acute respiratory disease in U.S. army trainees

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Gutless adenovirus: last-generation adenovirus for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

1 reference

7 January 2021

Use of replicating oncolytic adenoviruses in combination therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Protein toxins: intracellular trafficking for targeted therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

1 reference

7 January 2021

Recent progress in the battle between oncolytic viruses and tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immunotoxin therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Vector-mediated cancer gene therapy: an overview

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Progress and problems with the use of viral vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Gene therapy: twenty-first century medicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Update on adenovirus and its vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Adenoviral vector-mediated gene transfer for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Adenoviral vectors: systemic delivery and tumor targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Cancer gene therapy by adenovirus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Readministration of helper-dependent adenovirus to mouse lung

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Antisense c-myc fragments induce normal differentiation cycles in HL-60 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Adenovirus-mediated expression of both antisense ODC and AdoMetDC inhibited colorectal cancer cell growth in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Adenovirus-delivered antisense RNA and shRNA exhibit different silencing efficiencies for the endogenous transforming growth factor-beta (TGF-beta) type II receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Gene-based vaccines and immunotherapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

The three Es of cancer immunoediting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Modifying adenoviral vectors for use as gene-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Enhancement of Cancer Radiation Therapy by Use of Adenovirus-Mediated Secretable Glucose-Regulated Protein 94/gp96 Expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Adenovirus as vehicle for anticancer genetic immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

CD8 T-cell recognition of human 5T4 oncofetal antigen.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Genetic targeting strategies for adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Genetic retargeting of adenovirus: novel strategy employing "deknobbing" of the fiber

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Genetically targeted adenovirus vector directed to CD40-expressing cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single‐chain diabody (scDb) adapter that binds to fiber knob and HMWMAA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Binding and modulation of p53 by p300/CBP coactivators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Selectively replicating adenoviruses for oncolytic therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Targeted and shielded adenovectors for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immunotoxins and central nervous system neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Chemical construction of immunotoxins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immunotoxins for targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Immunotoxins containing Pseudomonas exotoxin A: a short history

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

A recombinant immunotoxin containing a disulfide-stabilized Fv fragment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Antibody conjugates and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

DNA bending is a determinant of calicheamicin target recognition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Monoclonal antibodies for the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

BL22 and lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Toxin-labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Genetic content and evolution of adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Adenovirus-based cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Antisense therapeutics: from theory to clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Targeted toxins as anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021

Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701054

7 January 2021